Promising results were also obtained with a treatment based on autologous glioma cells treated ex vivo with an antisense oligodeoxynucleotide targeting the IGF-IR (IGF-1R/AS ODN) and re-implanted in patients. Here, IGF1R is linked to central nervous system cancer.